Medical Market Report

Global Genomic Biomarker Market By Type (Oncology, Cardiology, Neurology, and Nephrology), By Application (Hospitals, and Diagnostic and research laboratories), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • 138844
  • 18-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    Global Genomic Biomarker Market is estimated to be valued US$ XX.X million in 2019. The report on Genomic Biomarker Market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, etc. for the forecast year up to 2029. The global genomic biomarker market is segmented on the basis of Type, Application, and geography.

    In 2019, the North America market is valued US$ XX.X million and the market share is estimated X.X%, and it is expected to be US$ XX.X million and X.X% in 2029, with a CAGR X.X% from 2020 to 2029.

    Genomic Biomarker Market Scope:

    By type, the market is segmented into Oncology, Cardiology, Neurology, and Nephrology. By Application, the market is divided into Hospitals, and Diagnostic and research laboratories.
    Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include Bio-Rad, Beckman Coulter, Myriad Genetics, Thermo Fisher Scientific, Roche, QIAGEN, Epigenomics, Almac, Pfizer, Human Longevity, ValiRx, Personalis, Eagle Genomics, Empire Genomics, Agilent, and Illumina.

    Key Market Segments

    Type

    Oncology

    Cardiology

    Neurology

    Nephrology

    Application

    Hospitals

    Diagnostic and research laboratories

    Key Market Players included in the report:

    Bio-Rad

    Beckman Coulter

    Myriad Genetics

    Thermo Fisher Scientific

    Roche

    QIAGEN

    Epigenomics

    Almac

    Pfizer

    Human Longevity

    ValiRx

    Personalis

    Eagle Genomics

    Empire Genomics

    Agilent

    Illumina

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and Genomic Biomarker Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Genomic Biomarker Market; high-growth regions; and market drivers, restraints, and also market chances.
    The analysis covers Genomic Biomarker Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Genomic Biomarker Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the Genomic Biomarker Market together side their company profiles, SWOT analysis, latest advancements, and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
    To know the Genomic Biomarker Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of Genomic Biomarker sub-markets, depending on key regions (various vital states).
    To analyze Genomic Biomarker Market concerning growth trends, prospects, and also their participation in the entire sector.
    To examine and study the Genomic Biomarker Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2013 to 2018, and also prediction to 2029.
    Primary worldwide Genomic Biomarker Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.

  • Table Of Content 
    1. Genomic Biomarker Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope
    

    2. Executive Summary
    

      2.1. Key Findings by Major Segments
    
  2.2. Top strategies by Major Players
    

    3. Global Genomic Biomarker Market Overview
    

    3.1. Genomic Biomarker Market Dynamics
    

        3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges
    

      3.2. PESTLE Analysis
    
  3.3. Opportunity Map Analysis
    
  3.4. PORTER’S Five Forces Analysis
    
  3.5. Market Competition Scenario Analysis
    
  3.6. Product Life Cycle Analysis
    
  3.7. Opportunity Orbits
    
  3.8. Production Analysis by Region/Company
    
  3.9. Industry chain Analysis
    
  3.10. Marketing Strategy
    

    4. Global Genomic Biomarker Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

      4.1. Global Genomic Biomarker Market Analysis by Type: Introduction
    
  4.2. Market Size and Forecast by Region
    
  4.3. Oncology
    

      4.4. Cardiology
    

      4.5. Neurology
    

      4.6. Nephrology
    

    5. Global Genomic Biomarker Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

      5.1. Global Genomic Biomarker Market Analysis by Application: Introduction
    
  5.2. Market Size and Forecast by Region
    
  5.3. Hospitals
    

      5.4. Diagnostic and research laboratories
    

    6. Global Genomic Biomarker Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

      6.1. North America
    

        6.1.1. North America Genomic Biomarker Market: Regional Trend Analysis
    

         6.1.1.1. US
    
     6.1.1.2. Canada
    
     6.1.1.3. Mexico
    

      6.2.1. Europe
    

        6.2.1. Europe Genomic Biomarker Market: Regional Trend Analysis
    

         6.2.1.1. Germany
    
     6.2.1.2. France
    
     6.2.1.3. UK
    
     6.2.1.4. Russia
    
     6.2.1.5. Italy
    
     6.2.1.6. Spain
    
     6.2.1.7. Rest of Europe
    

      6.3. Asia-Pacific
    

        6.3.1. Asia-Pacific Genomic Biomarker Market: Regional Trend Analysis
    

         6.3.1.1. China
    
     6.3.1.2. Japan
    
     6.3.1.3. Korea
    
     6.3.1.4. India
    
     6.3.1.5. Rest of Asia-Pacific
    

      6.4. Latin America
    

        6.4.1. Latin America Genomic Biomarker Market: Regional Trend Analysis
    

         6.4.1.1. Brazil
    
     6.4.1.2. Argentina
    
     6.4.1.3. Rest of Latin America
    

      6.5. Middle East and Africa
    

        6.5.1. Middle East and Africa Genomic Biomarker Market: Regional Trend Analysis
    

         6.5.1.1. GCC
    
     6.5.1.2. South Africa
    
     6.5.1.3. Israel
    
     6.5.1.4. Rest of MEA
    

    7. Global Genomic Biomarker Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

      7.1. Market Share Analysis
    
  7.2. Company Profiles
    
  7.3. Bio-Rad
    

        7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments
    

      7.4. Beckman Coulter
    

        7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments
    

      7.5. Myriad Genetics
    

        7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments
    

      7.6. Thermo Fisher Scientific
    

        7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments
    

      7.7. Roche
    

        7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments
    

      7.8. QIAGEN
    

        7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments
    

      7.9. Epigenomics
    

        7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments
    

      7.10. Almac
    

        7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments
    

      7.11. Pfizer
    

        7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments
    

      7.12. Human Longevity
    

        7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments
    

      7.13. ValiRx
    

        7.13.1. Company Overview
    
    7.13.2. Financial Highlights
    
    7.13.3. Product Portfolio
    
    7.13.4. SWOT Analysis
    
    7.13.5. Key Strategies and Developments
    

      7.14. Personalis
    

        7.14.1. Company Overview
    
    7.14.2. Financial Highlights
    
    7.14.3. Product Portfolio
    
    7.14.4. SWOT Analysis
    
    7.14.5. Key Strategies and Developments
    

      7.15. Eagle Genomics
    

        7.15.1. Company Overview
    
    7.15.2. Financial Highlights
    
    7.15.3. Product Portfolio
    
    7.15.4. SWOT Analysis
    
    7.15.5. Key Strategies and Developments
    

      7.16. Empire Genomics
    

        7.16.1. Company Overview
    
    7.16.2. Financial Highlights
    
    7.16.3. Product Portfolio
    
    7.16.4. SWOT Analysis
    
    7.16.5. Key Strategies and Developments
    

      7.17. Agilent
    

        7.17.1. Company Overview
    
    7.17.2. Financial Highlights
    
    7.17.3. Product Portfolio
    
    7.17.4. SWOT Analysis
    
    7.17.5. Key Strategies and Developments
    

      7.18. Illumina
    

        7.18.1. Company Overview
    
    7.18.2. Financial Highlights
    
    7.18.3. Product Portfolio
    
    7.18.4. SWOT Analysis
    
    7.18.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.